AOD-9604

Research-Grade

AOD-9604 is a synthetic modification of the growth-hormone fragment hGH(177-191), developed in the 1990s on the hypothesis that GH's lipolytic effects are localized to its C-terminus and can be isolated from its anabolic and insulin-antagonizing activities. Preclinical animal data initially suggested AOD-9604 could mobilize fat oxidation without raising IGF-1 or impairing glucose tolerance — a potentially attractive weight-loss profile. The clinical reality has been disappointing. Metabolic Pharmaceuticals advanced AOD-9604 through several phase-2 trials in humans with obesity. The largest trial (n≈534, 2007) reported weight-loss differences versus placebo that failed to meet the pre-specified primary endpoint, and a subsequent 6-month extension did not demonstrate meaningful additional weight reduction. The sponsor discontinued obesity development and the molecule was repositioned as a cosmetic/research ingredient. Despite thin clinical evidence, AOD-9604 remains heavily marketed in off-label weight-loss peptide circles. Oral and subcutaneous protocols circulate online without trial support. More recently it has appeared in compounded cosmetic injectables, primarily in Australia.